Green Cross (006280) was trading 100 won (0.08%) lower than the previous day during the morning session on the 21st.

IBK Investment & Securities projected that Green Cross's third-quarter operating profit this year will increase year-on-year, driven by a rising share of sales from high-margin products.

According to IBK Investment & Securities' estimates, Green Cross's consolidated revenue for the third quarter of 2026 is 524.4 billion won, with operating profit of 40.8 billion won. Revenue is expected to decline 14.0% year-on-year, while operating profit is projected to rise 39.8%. The estimated operating margin is 7.8%.

Compared with market consensus, revenue and operating profit are expected to move in opposite directions. Revenue is forecast to fall 7.9% short of the consensus (569.4 billion won), while operating profit is analyzed to exceed the consensus (36.4 billion won) by 12.1%.

As the background for this projected profit increase, IBK Investment & Securities cited the rising share of sales from high-margin products. Even with overall revenue declining, the firm assessed that changes in product mix will positively affect profitability. It also noted the expansion into a subcutaneous injection formulation, following the growth of the immunoglobulin product Aelyglo.

[This article is intended to provide information for investment reference and does not recommend buying or selling any specific stock. Figures may vary depending on market conditions. Investment decisions and any resulting responsibility rest with the investor. AI assisted in part.]